568 related articles for article (PubMed ID: 19092849)
41. Activation of the Syk tyrosine kinase is insufficient for downstream signal transduction in B lymphocytes.
Hsueh RC; Hammill AM; Lee JA; Uhr JW; Scheuermann RH
BMC Immunol; 2002 Dec; 3():16. PubMed ID: 12470302
[TBL] [Abstract][Full Text] [Related]
42. The B cell antigen receptor activates the Akt (protein kinase B)/glycogen synthase kinase-3 signaling pathway via phosphatidylinositol 3-kinase.
Gold MR; Scheid MP; Santos L; Dang-Lawson M; Roth RA; Matsuuchi L; Duronio V; Krebs DL
J Immunol; 1999 Aug; 163(4):1894-905. PubMed ID: 10438924
[TBL] [Abstract][Full Text] [Related]
43. Therapeutic potential of spleen tyrosine kinase inhibition for treating high-risk precursor B cell acute lymphoblastic leukemia.
Perova T; Grandal I; Nutter LM; Papp E; Matei IR; Beyene J; Kowalski PE; Hitzler JK; Minden MD; Guidos CJ; Danska JS
Sci Transl Med; 2014 May; 6(236):236ra62. PubMed ID: 24828076
[TBL] [Abstract][Full Text] [Related]
44. TOSO interacts with SYK and enhances BCR pathway activation in chronic lymphocytic leukemia.
Zhang YR; Yu Z; Xiong WJ; Liu XX; Liu HM; Cui R; Wang Q; Chen WM; Qiu LG; Yi SH
Chin Med J (Engl); 2020 Sep; 133(17):2090-2097. PubMed ID: 32784334
[TBL] [Abstract][Full Text] [Related]
45. Membrane-associated signaling in human B-lymphoma lines.
Tauzin S; Ding H; Burdevet D; Borisch B; Hoessli DC
Exp Cell Res; 2011 Jan; 317(2):151-62. PubMed ID: 20875408
[TBL] [Abstract][Full Text] [Related]
46. B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells.
Seda V; Mraz M
Eur J Haematol; 2015 Mar; 94(3):193-205. PubMed ID: 25080849
[TBL] [Abstract][Full Text] [Related]
47. Protein tyrosine phosphatase receptor-type O truncated (PTPROt) regulates SYK phosphorylation, proximal B-cell-receptor signaling, and cellular proliferation.
Chen L; Juszczynski P; Takeyama K; Aguiar RC; Shipp MA
Blood; 2006 Nov; 108(10):3428-33. PubMed ID: 16888096
[TBL] [Abstract][Full Text] [Related]
48. Syk-induced phosphatidylinositol-3-kinase activation in Epstein-Barr virus posttransplant lymphoproliferative disorder.
Hatton O; Lambert SL; Phillips LK; Vaysberg M; Natkunam Y; Esquivel CO; Krams SM; Martinez OM
Am J Transplant; 2013 Apr; 13(4):883-890. PubMed ID: 23398911
[TBL] [Abstract][Full Text] [Related]
49. The degree of BCR and NFAT activation predicts clinical outcomes in chronic lymphocytic leukemia.
Le Roy C; Deglesne PA; Chevallier N; Beitar T; Eclache V; Quettier M; Boubaya M; Letestu R; Lévy V; Ajchenbaum-Cymbalista F; Varin-Blank N
Blood; 2012 Jul; 120(2):356-65. PubMed ID: 22613791
[TBL] [Abstract][Full Text] [Related]
50. Multidimensional single-cell analysis of BCR signaling reveals proximal activation defect as a hallmark of chronic lymphocytic leukemia B cells.
Palomba ML; Piersanti K; Ziegler CG; Decker H; Cotari JW; Bantilan K; Rijo I; Gardner JR; Heaney M; Bemis D; Balderas R; Malek SN; Seymour E; Zelenetz AD; van den Brink MR; Altan-Bonnet G
PLoS One; 2014; 9(1):e79987. PubMed ID: 24489640
[TBL] [Abstract][Full Text] [Related]
51. Phosphorylation of spleen tyrosine kinase at tyrosine 348 (pSyk³⁴⁸) may be a marker of advanced phase of Chronic Myeloid Leukemia (CML).
Bourgne C; Janel A; Berger J; Rapatel C; Tournilhac O; Hermet E; Guerci A; Lioret F; Briançon A; Bamdad M; Boiret-Dupré N; Berger MG
Leuk Res; 2015 Mar; 39(3):329-34. PubMed ID: 25612940
[TBL] [Abstract][Full Text] [Related]
52. A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor.
Burke RT; Meadows S; Loriaux MM; Currie KS; Mitchell SA; Maciejewski P; Clarke AS; Dipaolo JA; Druker BJ; Lannutti BJ; Spurgeon SE
Oncotarget; 2014 Feb; 5(4):908-15. PubMed ID: 24659719
[TBL] [Abstract][Full Text] [Related]
53. Steroid effects on ZAP-70 and SYK in relation to apoptosis in poor prognosis chronic lymphocytic leukemia.
Boelens J; Lust S; Van Bockstaele F; Van Gele M; Janssens A; Derycke L; Vanhoecke B; Philippé J; Bracke M; Offner F
Leuk Res; 2009 Oct; 33(10):1335-43. PubMed ID: 19297020
[TBL] [Abstract][Full Text] [Related]
54. Spleen tyrosine kinase (Syk), a novel target of curcumin, is required for B lymphoma growth.
Gururajan M; Dasu T; Shahidain S; Jennings CD; Robertson DA; Rangnekar VM; Bondada S
J Immunol; 2007 Jan; 178(1):111-21. PubMed ID: 17182546
[TBL] [Abstract][Full Text] [Related]
55. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
Herman SE; Gordon AL; Hertlein E; Ramanunni A; Zhang X; Jaglowski S; Flynn J; Jones J; Blum KA; Buggy JJ; Hamdy A; Johnson AJ; Byrd JC
Blood; 2011 Jun; 117(23):6287-96. PubMed ID: 21422473
[TBL] [Abstract][Full Text] [Related]
56. B cell antigen receptor-induced activation of Akt promotes B cell survival and is dependent on Syk kinase.
Pogue SL; Kurosaki T; Bolen J; Herbst R
J Immunol; 2000 Aug; 165(3):1300-6. PubMed ID: 10903730
[TBL] [Abstract][Full Text] [Related]
57. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.
Coffey G; DeGuzman F; Inagaki M; Pak Y; Delaney SM; Ives D; Betz A; Jia ZJ; Pandey A; Baker D; Hollenbach SJ; Phillips DR; Sinha U
J Pharmacol Exp Ther; 2012 Feb; 340(2):350-9. PubMed ID: 22040680
[TBL] [Abstract][Full Text] [Related]
58. ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells.
Gobessi S; Laurenti L; Longo PG; Sica S; Leone G; Efremov DG
Blood; 2007 Mar; 109(5):2032-9. PubMed ID: 17038529
[TBL] [Abstract][Full Text] [Related]
59. Integration of innate into adaptive immune responses in ZAP-70-positive chronic lymphocytic leukemia.
Wagner M; Oelsner M; Moore A; Götte F; Kuhn PH; Haferlach T; Fiegl M; Bogner C; Baxter EJ; Peschel C; Follows GA; Ringshausen I
Blood; 2016 Jan; 127(4):436-48. PubMed ID: 26508782
[TBL] [Abstract][Full Text] [Related]
60. Correlation between ZAP-70, phospho-ZAP-70, and phospho-Syk expression in leukemic cells from patients with CLL.
Kaplan D; Meyerson HJ; Li X; Drasny C; Liu F; Costaldi M; Barr P; Lazarus HM
Cytometry B Clin Cytom; 2010 Mar; 78(2):115-22. PubMed ID: 20014315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
